Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here. 		Share with a colleague
Pharmaceutical Executive Europe E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
Survey
We asked 50 pharma leaders, how do you think the reputation of the pharma industry has changed in recent years?
Improved 3%

Stayed the same

 33%
Declined 64%

Talk to us:
jupton@advanstar.com

Advertise with us:
Dtaylor-higgins@advanstar.com
26 March, 2013
Behind AstraZeneca’s Latest R&D Cuts
AstraZeneca’s decision to cut 5,050 jobs by 2016 and cease R&D operations at its Alderley Park, UK, facility has many wondering where CEO Pascal Soriot plans to take the company ...Read more
Video: Pharm Exec's Brand of the Year 2013
Senior editor Ben Comer announces the winner of this year’s Pharm Exec Brand of the Year award and outlines the reasons for its selection ... Read more
Multichannel Pharma — Myth or Reality?
Sven Awege asks, is multichannel pharma a myth or reality? Or somewhere in between? And what should we be doing about it? ... Read more
Talent Management in Touch Times
Active management of high potential individuals and leadership development is the key to business success in a tough economic climate, writes RSA’s Nick Stephens ... Read more
Read the March Pharm Exec Global Digest
In this month’s issue: Seeing through EU Pricing Transparency; Global Patent Management Made Easy; Multichannel Pharma; Harnessing Positive Content for Reputation Management ... Read more
Also in this issue
Changing the DNA of Pharma Patent Adherence Programs
Are US and Canadian Rx Policies Converging?
Are You Ready for the Biologics Patent Cliff?